Home Multimedia Exclusive Videos Exclusive VideosMultimedia PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape Thursday, April 21, 2016 Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here. Advertisement Recent Articles Umbralisib Confers Durable Response, Tumor Reductions in Patients With Relapsed/Refractory Marginal Zone Lymphoma Thursday, May 23, 2019 While rituximab-based treatment has improved outcomes for patients with marginal zone lymphoma (MZL), most patients eventually have a disease relapse. According to results from... Transgene Levels Not Sufficient for Treatment Decisions in CAR T-Cell–Treated Patients Thursday, May 23, 2019 An analysis of three clinical trials of tisagenlecleucel found that levels of chimeric antigen receptor (CAR) transgene (or the gene that is artificially introduced... Gilteritinib Superior to Standard Chemotherapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia Thursday, May 23, 2019 Treatment with the oral FLT3/AXL inhibitor gilteritinib led to longer overall survival (OS) in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), compared with... Is There a Role for AHCT Consolidation in MCL in the Rituximab Era? Thursday, May 23, 2019 The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative... No Benefit in Adding Rituximab to MBVP in CNS Lymphoma Thursday, May 23, 2019 Results from a phase III trial suggest there is no survival benefit of adding the anti-CD20 monoclonal antibody rituximab to a standard methotrexate-based chemo-therapy... Current Issue May 2019, Volume 5, Issue 6 Wednesday, May 1, 2019 This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.